FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 41 filers reported holding FUSION PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $78,255,401 | +121.9% | 3,670,516 | 0.0% | 1.77% | +120.5% |
| Q4 2023 | $35,273,659 | +269.6% | 3,670,516 | 0.0% | 0.80% | -77.1% |
| Q3 2023 | $9,543,342 | -44.3% | 3,670,516 | 0.0% | 3.52% | -34.0% |
| Q2 2023 | $17,141,310 | +23.9% | 3,670,516 | 0.0% | 5.32% | +18.2% |
| Q1 2023 | $13,837,845 | +119583.8% | 3,670,516 | 0.0% | 4.50% | +33.8% |
| Q4 2022 | $11,562 | -99.9% | 3,670,516 | 0.0% | 3.36% | +3.5% |
| Q3 2022 | $11,048,000 | +20.9% | 3,670,516 | 0.0% | 3.25% | +39.2% |
| Q2 2022 | $9,140,000 | -68.0% | 3,670,516 | 0.0% | 2.34% | -56.7% |
| Q1 2022 | $28,520,000 | +86.3% | 3,670,516 | 0.0% | 5.39% | +209.5% |
| Q4 2021 | $15,306,000 | -47.3% | 3,670,516 | 0.0% | 1.74% | -31.7% |
| Q3 2021 | $29,070,000 | – | 3,670,516 | – | 2.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 3,502,425 | $39,994,000 | 10.54% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,670,516 | $44,120,000 | 8.88% |
| TPG Group Holdings (SBS) Advisors, Inc. | 2,551,794 | $30,673,000 | 0.55% |
| Orbimed Advisors | 3,224,770 | $38,762,000 | 0.49% |
| Perceptive Advisors | 2,235,983 | $26,877,000 | 0.39% |
| CLOUGH CAPITAL PARTNERS L P | 402,800 | $4,842,000 | 0.35% |
| Rock Springs Capital Management LP | 947,541 | $11,389,000 | 0.29% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 972,046 | $11,684,000 | 0.28% |
| CANADA PENSION PLAN INVESTMENT BOARD | 3,116,966 | $37,466,000 | 0.07% |
| Woodline Partners LP | 76,093 | $915,000 | 0.03% |